Under the Papacwork Readings Act of 1995, no Com-

EXPRESS MAIL NO. EV689730756U8

PTOISBASA (06-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

are required to respond its a collection of information unless it options a valid Chip control number.

Substitute for form 1 4490-TU

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Charles as many shirids as necessary)

Complete If Kriown					
Application Number	OB/234,208				
Filing Date	January 20, 1999				
First Named Investors	Dohianty				
Anunk	1842				
Examiner Name	Anne Holleran				
Attorney Docket Number	49821-1				

Exercises	A		U.S. PATENT	DOCUMENTS	
kritals"	Cita Ito.	Document Number NumberKind Code ^{2 (R Acces)}	Publication Date MM-QD-YYYY	Name of Paternes or Applicant of Clied Cocumus:	Pages, Columns, Lines, Where Relevant Passages or Refevan Figures Appear
_ 5%	C105	U9-6,541,214	04-01-2003	CSinton et al.	
	C106	US-20030059863	03-17-2003	Clinfon et al.	
	C107	US-20048022785	02-05-2004	Clinion at al.	
	C108	US-20040052796	53-18-2004	Clinitois et al.	
_ V	C109	US-5,705,167	01-08-1995	Greens of at	-
	C110	US-6,811,006	09-22-1996	Plowman et et.	
		US			
		US-			
		US-			
		us-			
		US			
		US-			
		US-			
		US-			
		US			
		US-		- Private	
		US-			
		US			

Cymerican	-	FORE	IGN PATENT DOCU	MENTS		-
Examinar Cite Initiate No.	Cite	Re Fortent Palent Desarrant	Publication	Mame of Peterses or	Pages, Columns, Lines, Where Relevant Passages Or Relevant Pigures Appear	Ť-
	100	Country Code -Number - Ried Code (Wincowe)	Dete 1997	Applicant of Clied Document		T
SM	C111	WD0029689	05-25-2000	Oragon Health Sciences University		Γ
	CHIZ	WC100444503	08-03-2000	Oregon Health Sciences University		
	Cita	W00161356	08-23-2001	Oregon Health Sciences University		
	GIM	WO0214470	03-21-2002	Oregon Health and Sidence University		
	C115	W055018988	02-24-05	Receptor BioLogix, Inc.		

Part Land	 	
Exemple 1	Date	71 / 1
Signistum ()		-1-12 Z10d
Λ	 Consideral	

Example: Initial if reference considered, which is or not cluston is in conformation with MPEP 809. Draw line through citation if not in conformation and sol considered, include copy of this form with eart communication is applicant. Applicant's unique citation designation number (optional). See Kinds: Codes of USPTO Parent Documents at term, isoto gar or MPEP 901.04 Enter Office that is guest the document, by the top-letter code (WIPTO Standard ST. 3). Por Vispanista patent documents, the indication of the year of the retar of the Emperor must precede the sental number of the patent document. After deformance of the patent document, and indicated on the document is the properties sympote as indicated on the document index WIPO Standard St. 10 if possible. Applicant is to place a check mark

Kind of document by the appropriate symbols as indicated on the document-under WIPO Standard St. 10 it possess. "Appacam is an account much their if English language principles in standard.
This consists language the indicated by 3T CFR 1.9T and 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidenticity is governed by 35 U.S.C. 122 and 3T CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to compete the form and/or suggestions for relativishing this burden, should be sent to the Chief information.

SEA 1628029v1 49321-1

PTOS BURBE (05.00)
Apparatured for use through 04/30/2003, CAB 0651-003
U.S. Patént and Trademark Conce; U.S. DEPARTMENT OF COMMERCI
Under the Paperwork Reduction Act of 1995,no paraces are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	09/234,208	
STATEMENT BY APPLICANT	Piling Oate	January 20, 1999	
(Use as many sheets as declassity)	Piret Named Inventor	Doherty.	
	Art Unit	1642	
	Examiner Name	Anne Holleran	
Sheet 2 of 5	Attorney Docket Number	49321-1	

Examiner	Oto	NON PATENT LITERATURE DOCUMENTS	
initials.	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city antior country where published.	T
gu C116		BAASNER et al., Reversible tumorigenesis in mice by conditional expression of the HER2/c-en62 receptor tyrosine kinake, Oncogene 13(5):901-11, 1996	
	C117	BOWIE et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Subatituitions, Science 247:1306-1310, 1990	
	C118	BRANDON et al., Estrogen Receptor Gene Expression in Human Uterine Lelomyomata, J. Clin. Endocrinol. Metab. 80(8):1876-1881, 1995	
	C119	BRANDON et al., Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine lejomyomas, Am. J. Obstet. Gymecot. 166(1):78-85, 1993	
	C120	BRODOWICZ et al., Soluble HER-2/neu netralizes biologic effects of anti-HER-2/new antibody on breast caricer cells in visio, Int. J. Cancer 73:875-879, 1987.	:
	C121	BROWN et at., Artibodies against Highly Conserved Sites in the Epidermal Growth Factor Receptor Tyrosine Kinase Bornain as Probes for Structure and Function, Biochem 32:4659- 4654, 1993	
	C122	BURGESS et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. Cell Blol. 111:2129-2138, 1990	
	C123	CLINTON and BROWN, Generation and Use of Anti-peptide Antibodies Directed against Catalytic Domain of Protein Kinases, Methods In Enzymol. 200:463-474, 1991	
	C124	CLINTON and HUA, Estrogen action in human ovarian cancer; Crit. Rev. Oncol/Heimatol. 25:1-9, 1997	Ŧ
Ø	O125	CLINTON et al., Estrogens increase the expression of fibutin-1, an extracellular matrix protein secreted by human overien carioer cells, Proc. Natl. Acad. Sci. UBA 93:318-320, 1998	

1 pm 7/23/05

SEA 1628029v1 49321-)

USPTO USPTO TO: peter reddi COMPANY:

**************************************	7		_
5u	C126	DERMER, Another Anniversary for the War on Cancer, Blo/Technology 12:320, 1994	L
	C127	DI FIORE et al., erb8-2 is a Potent Oncogene When Overexpressed in NIH/3T3 Cells, Science 237:178-182, 1987	
	C128	DILLMAN, Antibodias as Cytofoxic Tharapy, J. Can. Oncol. 12(7):1497-1515, 1894	
	G129	DOHERTY et al., An Alternative HER-2/neu Transcript of 8 kb Has an Extended 3'UTR and Displays incressed Stability in SKOV-3 Overlan Carcinome Cells, Gynecol, Oncol, 74:408-415, 1999	
	C130	DOUGALL et al., The new oncogene: signal transduction pathways, transformation mechanisms and evolving therapies, Oncogene 9:2709-2123, 1994	
	G131	GREENSPAN and DI CERA, Dafining epitopes: It's not as easy as it seems, Nature Biotechn. 17:938-937, 1999	
	C132	HUA et al., SKOV3 Overlan Carcinoma Celle Have Functional Estrogen Receptor but are Growth-resistant to Estrogen and antiestrogens, J. Steroid Blochem. Molec. Biol. 55(3/4):279-289, 1995	
	C133	HUDZIAK et al., increased expression of the putative growth factor receptor p185 ¹²⁹⁹² causes transformation and turnorigenesis of NBH 313 cells, Proc. Natl. Acad. Sci. USA 84:7159-7163, 1987	
	C134	HYNES and STERN. The biology of erb8-2/neu/HER-2 and its role in cancer, Blochimics et Biophysica Acta 1198:185-184, 1994	
	C(35	JHABVALA-ROMERO et al., Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes temporien resistance in breast cancer cells that overexpress HER-2, Oncogene 22:8178-8186, 2003	
	C136	JUSTMAN and CLINTON, Heritatin, an AutoInhibitor of the Human epidermal Growth Factor Receptor 2 Tyrosine Kinsse, Modulates Epidermal Growth Factor Signaling Pathways Resulting in Growth Arrest, J. Biol. Chem. 277(23):20818-20824, 2002	
	C137	KERN et al., inhibition of Human Lung Cencer Cell Line Growth by an Anti-p185 ^{HER2} Antibody. Am. J. Respir. Cell Mol. Biol. 9:448-454, 1993	
$/\!\!\!/$	C138	LAZAR ét al., Transforming Growth Factor o.: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell. Biol. 8(3):1247-1252, 1988	
	C139	LEE and CLINTON, Serum Tyrosine Kinaise Activity and Neoplastic Disease, Recent Results Cancer Res. 113:32-40, 1989	
V	Ç14Q	LEWIS et al., Differential responses of human tumor cell lines to enti-p185*** monoclonal antibodies, Cancer Immunot. Immunother 37:255-263, 1993	
i628029vi	4932[-]	1 p 7/20/05	

> TO: peter reddi COMPANY: OTGSU

	1		
çu	C141	LIN and CLINTON, A soluble protein related to the HER-2 proso-oricogene product is released from human breast carcinoma cells. Oncogene 8(4):639-643, 1991	
	C142	LIN and CLINTON, Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity, Blochem, J. 235:051-367, 1986	
	C143	LIN and Clinton, The Epidermal Growth Factor Receptor from Prostate Cells to Dephosphorytated by a Prostate-Specific Phosphotyrosyl Phosphatase, Mol. Cell Biol. 8(12): 5477-5485, 1988	:
	C144	LIN et al., Chartectertzellon of Tyrosyl Kinasa Activity in Human Serum, J. Biol. Chem. 260(3): 1582-1587, 1985	
	C145	UN et al., Developmental Expression of Tyrosyl Kinase Activity in Human Serum, Human Biol. 56(3):549-556, 1987	
	C148	UN et al., Disuffice-Linked and Noncovalent Dimers of p185 ^{149,2} in Human Breast Carcinoma Cella, J. Cell. Biochem. 49:290-295, 1992	
	C147	LIN et at., insulin and epidermal growth factor stimulate phosphorytation of p185 ^{HER3} in the breast parcinoma cell line, 97474, Mol. Cell Endocrinol, 68(2-3):111-119, 1990	
	C148	LIN et al., Tyrosyf Kinase Activity is inversely Related to Prostetic Activ Phosphatase Activity in Two Human Prostate Carolnoma Cett Lines, Mol. Cett Biol. 8(12): 4753-4757, 1986	
	C149	LIU et al., MCF-7 breast cancer cells overexpressing transfected c-erb8-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and temoxifen-sensitivity anviso, Breast Cancer Res. Treatment 34:97-117, 1986	
	C150	MOLINA et al., NH ₂ -terminal Truncated HER-2 Protein but not Full-Length Receptor le Associated with Nodel Metastasis in Human Breast Cancer, Clin. Cancer Res. 8:347-363, 2002	
	C151	NATALLet al., Expression of the p185 encoded by HER2 oncogens in normal and transformed format this uses, Int. J. Gander 45:457-461, 1990.	
	C152	O'ROURICE et al., Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains, Proc. Natl. Acad. Sci. USA 94:3250-3255, 1997	
	Ci53	PIETRAS et al., HER-2 tyrosine kinase palitivay targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells, Oncogene 10:2435-2446, 1995	
	C154	SEVERINO et al., Rapid loss of asstrogen and progesterone receptors in human leiomyoma and myometrial explaint cultures, Mol. Human Repro. 2(11):823-828, 1996	
1	C155	SHAMIEH et al., Receptor binding specificiles of Herstatin and its intron 8-encoded domain, FEBS Letters 568:163-169, 2004	
A 1628029 √ atlie	1 49321-1	d. you 7/23/05	

TO: peter reddi COMPANY: OTGSU

G	C156	SHEPARD et al., Monoclonal antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic, J. Clin. Immunol, 11(3):117-127, 1991	
	C157	STAVEROSKY et.al., Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma, Clin, Cancer Res. 11(1):335-40, 2005	
	C158	TZAHAR et al., Bivatence of EGF-like ligands drives the ErbB signaling natwork, EMBO Journal 18(16):4938-4950, 1997	
	C159	Uniprot Data base, Database accession No. ERB2_HUMAN, "Receptor tyrosine-protein kinese erb8-2 precursor," 8/13/87, www.ebl.uniprot.org/uniprot- sry/uniProt/iew.do?protein[D=ER82_HUMAN&pager.ofset=null	
1	C160	XIA et el., Combination of EGFR, HER-2/mau, and HER-3 is a Stronger Predictor for the Outcome of One Squamous Cell Carcinoma Than Aby Individual Family Members, Clin. Gencer Res. 5:4164-4174, 1999	

C_{-}	
Example	
	- F
Signature 1 1 2 2	
Considered 7 1750	

. . .

^{*}EXAMPLER: Initial if reference consiglied, whether or not chatten is in conformation with MPEP 609. Draw fine through distinct in out in conformation and set considered. Include copy of this form with next communication to applicant.

*Applicant's unique clistics designation number (optional). *Applicant is to place a check must have if English language Translation is effectived.

This collection of information is required by 37 CFR 1.89. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO) to precesse) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated in take 120 orbitalies to complete, including gathering, preparing, and submitting the confidented applicants on the introduction of the amount of lines you require to compete this form another suggestions for reducing this burden, should be sent to the Chell Information Officer, U.S. Patent and Tradormali Officer, U.S. Dispertment of Commission, P.O. Box 1450, Alexandris, VA. 22313-1450. DO NOT GEND FEES OR COMPLETED FORMS TO THIS ADDRESS. GEND TO: Commissioner for Parantes, P.O. Box 1450, Alexandris, VA. 22313-1450.

EXPRESS MAIL NO. EV784506051US

PTO/SE/06Å 406-03

U.S. Palent and Tradement for use imposed 67(31/2008, CARS (0661-003)

U.S. Palent and Tradement Office, U.S. DEPARTMENT OF COMMERCE

the Papernesis Reduction Act of 1965, no persons are negated to respond to a collection of information unless is dominate a until CARS control number.

Substitute for form	n 1449/PTO	Co	Complete If Known		
INFORM	ATION DISCLOSURE	Application Number Filing Date	09/234 208. January 20, 1899		
STATEN	IENT BY APPLICANT	First Named Inventor Art Unit	Doherty 1842		
(Use s	re many sheets as necessary)	Examiner Name	Susun Ungar		
Sheet 1	d 1	Attorney Docket Number:	48321-1		

Exercises	T TOBA		U.S. PATENT DO	CUMENTS	
Initials*	CSto.	Document Number	Publication Date Law-DD-YYYY	Home of Patentee or	Pages, Columns, Lines, Where
		Number-Kind Code ^{2 (Klosmy)}		Applicant of Ched Document	Pages, Columns, Lines, Where Relevant Passages or Reterent Figures Appear
		US-			
		us-			
		us:			
.,		us-			
		US-		···	
		US-			
		US			
		US-			
		us		, , , , , , , , , , , , , , , , , , ,	
		ius-			
		UB-			
		us-			<u> </u>
		U\$-			1
		us			
]		US-			1

Examples Initiata*	Cates No:	Foreign Potent Obcurrens Country Code ³ Muniber ⁴ Mind Code ³ of Immed	GN PATENT DOCUM Publication Date MALDD-YYYY	Name of Palegage of Applicant of Ched Dopument	Pages, Columno, Lines, Where Retayant Passages Or Retayant Figures Appear	Ť
9/	C115	WO06/016966	03-24-05	Receptor Blokoglis, Inc.		Г
<u> </u>						Г
						Г
		j.	"			-

Com ACI			
Examiner	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1	7
City and a second	1 2 . C . C . C	Date	""
adiam's			
		CORRORRO	1 1 X 7 O C
-	UL PAR . P		

Exempted: Initial fireference consistency, whether or not challen is in conformation with MPEP 809. Draw time through clastics if not in conformation and not consistency. Include copy of this form with next corrections to explicant. Applicant's unique clastics designation, number (options). See Kinds Codes of USPTO Potent Occaments at any testing or MPEP 801.04. Error of the best leasued the decignation, number (options). See Kinds Codes of USPTO Potent Occaments, the indication of the year of the proper must precede the serial number of the patent document. With of document by the appropriate symbols as staticated on the document under WIPO Standard St. 18 if possible, "Applicant is to pleas a check mark hard if document by the appropriate symbols as staticated.

This collection of information is registed by 37 DFR 1.97 and 1.98. The information is regard to obtain or ration a benefit by the public within to the WIPO is process) as applicables. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is astimized to take 2 hours to complete, including gathering, preceding, and submitting the completed application for the USPTD. This will very depending upon the individual case. Any compense on the smooth of time you require to compete this form endor suggestions for reducing this burden, should be sent to the Chief thermation of the process of the process of the Chief thermation of the USPTD. The arm I Lademant Office, U.S. Petent and Lademant Office, U.S. Department of Commissioner for Patante, P.O. Box 1450, Alexandria, VA 22313-1450.

Byou meed anxiotance in completing the completing the process. P.O. Box 1450, Alexandria, VA 22313-1450.

SEA 1805709+1 49321-1